Skip to content
#gene editing Open access

Decoupling reactogenicity from efficacy enables safer mRNA vaccines, AAV gene delivery, and in vivo base editing.

Sep 2026 · Molecular Therapy · 0 citations
Medicine

TL;DR

A unifying innate-sensing architecture for nucleic-acid therapeutics is defined and it is established that reactogenicity is not required for effective vaccination or gene delivery, enabling a broadly applicable strategy to widen the safety window of mRNA medicines, viral vectors, and in vivo genome editing.

Abstract

Nucleic-acid therapeutics, including mRNA vaccines, genome editors, and viral vectors, are constrained by acute innate reactogenicity that limits dosing flexibility, tissue targeting, and safety. Here we identify a conserved early innate inflammatory program, peaking approximately six hours after administration, that governs reactogenicity across mRNA formulated lipid nanoparticle (LNP), adenoviral vectors and AAV9. Using pharmacological and biochemical probes, we show that this program is driven predominantly by nucleic-acid cargo sensing, rather than lipid components, and is mechanistically separable from antigen expression, adaptive immune priming, and in vivo genome-editing efficacy. Selective modulation of this early cytokine burst achieved here using endosomal nucleic-acid sensing suppressors markedly reduces reactogenicity in multiple mouse models while preserving humoral and cellular immunity to mRNA vaccines, maintaining transgene expression, protecting blood-brain barrier integrity during stereotactic AAV9 delivery, and mitigating LNP-associated hepatotoxicity and thrombocytopenia. These findings define a unifying innate-sensing architecture for nucleic-acid therapeutics and establish that reactogenicity is not required for effective vaccination or gene delivery, enabling a broadly applicable strategy to widen the safety window of mRNA medicines, viral vectors, and in vivo genome editing.

Read PDF

Similar papers

Review Open access Sep 2026

Peptide-mediated CRISPR delivery: From dish to bloodstream.

The next decade of peptide-mediated delivery must reconcile the conservative demands of clinical translation with radical chemical innovation, and engineered peptides might overcome the restrictions of viruses and LNPs, providing a truly versatile platform for systemic CRISPR delivery.

A. Ressnerova, Ross C. Wilson · 0 citations
Review Open access Aug 2026

RNA vaccines in motion: A multidisciplinary exploration of design, delivery, and deployment

Overall, continued refinement of RNA sequence engineering and delivery systems positions these platforms as flexible tools for rapid-response vaccination and therapy, especially where fast antigen adaptation and scalable production are required.

Qamar Abuhassan, Ahmed Aldulaimi, O. Waleed et al. · 0 citations
Review Open access Aug 2026

Targeted delivery of mRNA to immune cells for in vivo cell therapy

The integration of rational material design, high-throughput screening, artificial intelligence, and interdisciplinary collaboration will be essential to advance next-generation targeted in vivo mRNA cell therapies toward clinical translation.

Danyang Wang, Yumin Li, Jinfeng Deng et al. · 0 citations
#gene editing Review Open access Aug 2026

Recent Advances in Non-Viral Vectors for Gene Therapy and Gene Delivery: From Lipid Nanoparticles to Engineered Extracellular Vesicles

This review summarizes recent advances in non-viral gene-delivery platforms, compares their strengths and limitations, and discusses future directions in cell-selective delivery, endosomal escape, transient delivery of genome-editing machinery, engineered EVs, hybrid vectors, and manufacturing-oriented development.

Yong-Feng Yang, Ting-Ting Song, Kai-Li Huang et al. · 0 citations
#gene editing Review Open access Sep 2026

Overview of Delivery Methods for Gene Editing.

This chapter emphasizes that the strategic selection of a delivery vehicle must be harmonized with the specific cargo and the unique biological requirements of the target tissue to ensure therapeutic success.

B. Debelec-Butuner · 0 citations

Related blog posts

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.